Article Information
History
- March 24, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Daniel Blanco-Melo1,2,*,
- Benjamin E. Nilsson-Payant1,2,*,
- Wen-Chun Liu1,3,*,
- Rasmus Møller1,2,
- Maryline Panis1,2,
- David Sachs4,
- Randy A. Albrecht1,3,# and
- Benjamin R. tenOever1,2,3,#
- 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
- 2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
- 3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA
- 4Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
- ↵#Corresponding author, email: benjamin.tenoever{at}mssm.edu
↵* Authors contributed equally
Posted March 24, 2020.
SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
